AN2 Therapeutics enters $80 million at-the-market equity sales agreement with Jefferies

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTX

0.00
  • AN2 Therapeutics entered an at-the-market equity distribution agreement with Jefferies for up to USD 80 million of common stock.
  • Jefferies will act as sales agent, earning commission up to 3% of gross proceeds.
  • Agreement allows sales from time to time on Nasdaq Global Select Market, subject to company instructions.
  • AN2 terminated prior ATM sales agreement with TD Securities, under which it sold 2,502,000 shares for USD 20,016,251.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-149822), on April 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.